DexCom will likely make significant headway in its addressable market in the next five years. The company should also increase its reach by launching new products and entering new countries. Despite a ...

DexCom showed strong growth, margin expansion, and Stelo's OTC launch unlocked new markets despite competitive and regulatory ...

What Happened? A number of stocks fell in the afternoon session after worries over worsening trade relations with China were ...

We recently compiled a list of the 12 Best Healthcare Stocks to Buy and Hold for 5 Years. DexCom, Inc. is one of them.

Medical device company DexCom (NASDAQ:DXCM) announced in Q1 CY2025, with sales up 12.5% year on year to $1.04 billion. The company expects the full year’s revenue to be around $4.6 billion, close to ...

Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the ...

After a report was released by short-sellers last month highlighting threats facing the company, shares in DexCom (NASDAQ: DXCM) stumbled 14.5% in March, according to S&P Global Market Intelligence.

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ: DXCM) has made meaningful progress on several fronts. The company launched new products in the continuous glucose ...